HOME >> BIOLOGY >> NEWS
Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better

s as a surrogate marker in short phase II/III human trials as it is clear that PSA values are accurately reflecting the inhibiting activity of the lycopene and vitamin E on tumour growth.

"What was particularly marked was that it was the low dose of both lycopene and vitamin E that was the most effective, demonstrating that 'more does not necessarily equal better'. Many pharmacological agents and natural compounds follow a bell-shaped dose response curve, which means that very low or high doses may not work and that there is an optimal dose between the two extremes."

The study showed that the lycopene and vitamin E were effectively taken up in the mice prostates in the same form as they are in humans, said Dr. Limpens.

Dr. Limpens said the findings seem promising, but it was early days yet and the Phase II trial in Germany was designed to verify whether a similar treatment to that used in the mice could alter the course of minimal clinical disease in patients. The lycopene product used (LycoVit)[3], has received the Generally Recognized as Safe (GRAS) status from the United States Food and Drug Administration (FDA) and can be used to fortify foods.

It was too early, said Dr. Limpens, to say whether lycopene and vitamin E could ever be used to prevent prostate cancer in healthy individuals. The first step was to see the results from the studies on men with prostate cancer: changes may, for example, be necessary to optimise the treatment. And before any preventative trials could even be considered it would be essential to verify the compound's potential to really prevent the development of cancer in a mouse model.

"However, our data fit in with the general picture that lycopene and vitamin E may have chemopreventative effects on prostate cancer. Therefore we would certainly recommend that all men regularly eat lycopene and vitamin E-rich foods: for example, all kinds of processed tomato products, papayas, pink grapefruit and w
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
30-Sep-2004


Page: 1 2 3

Related biology news :

1. Lycopenes anti-cancer effect linked to other tomato components
2. Slow-moving ground water slows down water-quality improvements in Chesapeake Bay
3. Cellular fat sensor slows heart disease
4. Ocean plant life slows down and absorbs less carbon
5. Gene therapy prolongs survival, slows disease progression in ALS mice
6. Even in middle age, cutting calories slows aging of the heart
7. Study suggests coenzyme Q10 slows functional decline in Parkinsons disease
8. Networking slows down protein evolution, study reveals
9. Alcohol-intoxication slows bodys efforts to restore normal blood pressure after small blood loss
10. UT Southwestern researchers discover how common MS drug slows progression of the disease
11. Alcohol researchers show friendly virus slows HIV cell growth

Post Your Comments:
(Date:2/10/2015)... Mass., Feb. 10, 2015  Alere Inc. (NYSE: ... its financial results for the quarter ended December ... Officer and President of Alere said, "We made ... Alere as the global leader in rapid diagnostics ... the Alere Health divestiture in early January enabled ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
(Date:3/5/2015)... March 05, 2015 RMI ... and chronic orthopedic conditions such as meniscal tears, ... elbow, and joint pain due to degenerative conditions ... during orthopedic surgeries to promote better post-surgical outcomes. ... in nearly pain-free bone marrow harvesting with two ...
(Date:3/4/2015)... March 04, 2015 USDM Life ... the life sciences industry, hired David Blewitt ... Cloud Compliance Services and Solutions at USDM Life ... based applications while maintaining compliance with government regulations worldwide. ... been an accomplished life sciences regulatory and IS compliance ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... Launched by the Assistance ... in December 2011, ,SARAH, - the French national ... sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled more ... SARAH, a large French study of patients with ... has completed patient enrolment, exceeding its 400-patient target, according ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
Cached News: